Skip to main content

Table 1 Characteristics of included randomized controlled trials

From: Oral and injectable Marsdenia tenacissima extract (MTE) as adjuvant therapy to chemotherapy for gastric cancer: a systematic review

Study No. of patients Stage of gastric cancer MTE (type and dose) Chemotherapy regimen for both groups Co-intervention for side effects Length of follow up (week) Outcome
MTE group Control group
Deng 2016 [20] 15 15 Advanced MTE injection, 80 ml/d for 7 d, 2 sessions TP 5-HT3 antagonists 6 a,b,c
Gao 2015 [21] 92 91 Advanced MTE injection, 40 ml/d for 14 d, 2 sessions XELOX Tropisetron and CSF 16 a,c,d,e,g
Gao 2017 [22] 33 33 IV MTE injection, 80 ml/d for 14 d, 4 sessions TP NR 12 a,b,c,d,e,g
Huang 2013 [23] 36 36 Early stage with radical gastrectomy MTE tablet, 2.4 g/time, 3 times/d for 30 d, 2 sessions FOIFOX/XELOX/EOF NR 26 c,d,
Huo 2009 [24] 31 31 Advanced MTE tablet, 2.4 g/time, 3 times/d for 30 d, 2 sessions FOIFOX Granisetron 8 a
Keyoumu 2012 [25] 33 35 III and IV MTE injection, 60 ml/d for 7 d, 2 sessions FOLFOX Ondansetron 14.2 a,b,c,d,e,g,h
Li 2016 [26] 60 60 IV MTE injection, 80 ml/d for 14 d, 4 sessions CPT-11 NR 8 a,c,e,g,h,i
Lin 2015 [27] 28 28 Advanced MTE injection, 60 ml/d for 14 d, 2 sessions XELOX Tropisetron, metoclopramide, vitamin B6, and CSF 6 a,b,c,d,e,f,g,i
Liu 2012 [28] 28 28 IV MTE injection, 80 ml/d for 7 d, 4 sessions FOLFOX 5-HT3 antagonists 8 a,c,d,e,f,g
Liu 2017 [29] 48 48 III and IV MTE injection, 60 ml/d for 14 d, 2 sessions SOX Palonosetron and metoclopramide 12 a,b,c,d,g,h,i
Ma 2015 [30] 23 23 Advanced MTE injection, 60 ml/d for 7 d, 2 sessions SOX NR 6 b,c
Shi 2017 [31] 53 53 Early stage with radical gastrectomy MTE tablet, 2.4 g/time, 3 times/d for 30 d, 2 sessions EOF/OLF NR 26 c,d,
Xiong 2015 [32] 32 32 IV MTE injection, 80 ml/d for 21 d, 4 sessions chemotherapy Vitamin 12 a,g,i,j
Zhang HY 2015 [33] 46 46 III and IV MTE capsule, 2.0 g/time, 2 times/d for 30 d, 2 sessions PF NR 8 a,b,c,d
Zhang H 2015 [34] 25 23 Advanced MTE injection, 40 ml/d for 14 d, 2 sessions XELOX CSF 6 a,b,c,d,e,f,g,h
Zheng 2017 [35] 42 42 III and IV MTE injection, 60 ml/d for 21 d, 2 sessions chemotherapy NR 18 a,c,d,e,g,h,i,j
Zhu 2017 [36] 40 40 Advanced MTE injection, 60 ml/d for 14 d, 4 sessions FOLFOX Tropisetron 8 a,c,d,e,g,h
  1. Abbreviations: T trial group; C control group; MTE Marsdenia tenacissima extract; NR not reported; FOLFOX folinic acid + fluorouracil + oxaliplatin; XELOX capecitabine + oxaliplatin; TP docetaxel + cisplatin; SOX S-1 + oxaliplatin; EOF epirubicin + oxaliplatin + fluorouracil; OLF oxaliplatin + leucovorin + flurouracil; CPT-11 irinotecan; PF cabazitaxel + Platinum + fluorouracil; CSF colony stimulating factor
  2. Outcomes: a = response to treatment; b = performance status; c = myelosuppression; d = gastrointestinal reactions; e = hepatic injury; f = kidney injury; g = neurotoxicity; h = oral mucosal lesions; i = progression-free survival; j = overall survival